Every material Form 8-K Biohaven Ltd. has filed with the SEC since October 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Biohaven reported a third-quarter 2026 net loss of $129.3 million, or $0.86 per share, compared with $173.4 million, or $1.64 per share, a year earlier, as research and development spending fell to $101.9 million from $141.2 million. The company also announced an Ono Pharmaceutical license for its MoDE IgG degrader portfolio, with up to $100 million in near-term payments, and said its SK Biopharmaceuticals license for opakalim will bring $400 million in cash consideration once it closes. Shareholders' equity was a deficit of $98.2 million at September 30, 2026.
Net loss of $129.3 million ($0.86 per share) for Q3 2026, versus $173.4 million ($1.64 per share) in Q3 2025
R&D expenses were $101.9 million, down from $141.2 million; G&A expenses were $24.6 million, down from $28.2 million
Ono license: up to $100 million in near-term payments, including $80 million received to date
SK Biopharmaceuticals deal: $400 million cash consideration, with $350 million payable at closing; HSR waiting period expired October 28, 2026
Biohaven said the FDA accepted its new drug application resubmission for Vyglxia (troriluzole) in spinocerebellar ataxia (SCA) and considers it a complete response to the November 4, 2025 action letter. The FDA set a user fee goal date in the first quarter of 2027 and plans an advisory committee meeting, with the date to be announced later, so approval is not assured.
FDA accepted the NDA resubmission for Vyglxia (troriluzole) in SCA, which includes new supportive analyses.
FDA considers the resubmission a complete response to the November 4, 2025 action letter.
User fee goal date set for the first quarter of 2027; advisory committee meeting date to be announced in the near term.
Biohaven entered into a Collaboration and License Agreement with Ono Pharmaceutical dated October 8, 2026, granting Ono an exclusive, royalty-bearing license to develop and commercialize its MoDE pan IgG degrader portfolio in Japan, South Korea, Taiwan and the ASEAN countries. Biohaven retains rights outside that territory, including the United States, Europe and China. The deal provides Biohaven up to $100 million in near-term payments, which the company says is non-dilutive capital.
Ono pays a one-time, non-refundable upfront payment of $80 million upon closing.
Biohaven is eligible for another $20 million upon a milestone, tied to Ono's stability test results and its election to continue development; the press release anticipates this milestone within a year.
Ono will pay royalties of approximately 20% on net sales of licensed products in the licensed territory, subject to specified reductions.
Ono may terminate the agreement for convenience on specified prior written notice, in whole or by product or country.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Biohaven Ltd. filing is on SEC EDGAR ↗. 8-K briefs of other companies →